SynthesisNutrition journal2026
Effects of resistant dextrin on glycemic traits: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Nutrition journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChronic hyperglycemia has affected billions of people currently and has emerged as an alarming public health concern for decades. Resistant dextrin (RD), an indigestible glucan with various applications in the food industry, has been reported to improve insulin sensitivity and help blood glucose control. However, the effect of RD on glucose metabolism was not systematically and comprehensively reviewed. The present study aimed to investigate the effect of RD on glycemic markers, including fasting blood glucose (FBG), fasting blood insulin (FBI), glycated hemoglobin (HbA1c), and homeostasis model assessment of insulin resistance (HOMA-IR).
methodsPubMed, Embase, Web of Science, Scopus, Cochrane library databases, and other additional records were systematically retrieved for randomized controlled trials (RCTs) on the effect of resistant dextrin intervention on FBG, FBI, HbA1c, HOMA-IR up to October 2024. Data were pooled using weighted mean difference (WMD) and 95% confidence intervals (95%CI), with P value ≤ 0.05 as statistical significance. Risk of bias was assessed with the Cochrane tool. Certainty of evidence was assessed with Grading of Recommendations Assessment, Development and Evaluation approach.
resultsA total of 13 RCTs were eligible. RD significantly reduced FBG (WMD: -0.15 mmol/L, 95%CI: -0.30 to -0.00 mmol/L; P = 0.049; I2 = 77.5%; 13 trials; 952 participants) and HOMA-IR (WMD: -0.51; 95% CI: -0.93 to -0.09; P = 0.02; I2 = 25.2%; 7 trials;332 participants), while modestly improved HbA1c (WMD: -0.18%; 95%CI: -0.39 to 0.02%; P = 0.07; I2 = 62.0%; 10 trials; 788 participants). The effect of RD on FBI was not significant (WMD: -4.26 pmol/L; 95%CI: -13.05 to 4.53 pmol/L; P = 0.29; I2 = 65.0%; 8 trials; 625 participants). Subgroup analysis revealed that RD was more beneficial to overweight/obese or diabetic patients than the non-obese and non-diabetic. A dosage of 10 g per day was the most frequently used dose that showed efficacy.
conclusionThis study is so far the most extensive systematic review to evaluate the role of RD on markers of glycemic control. RD interventions can exert beneficial effects on FBG and HOMA-IR. Further high-quality and long-term studies are needed to strengthen its credibility.
trial registrationThis systematic review was registered on PROSPERO (international prospective register of systematic reviews) as CRD42023429881.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.